Avenira Limited (AU:AEV) has released an update.
Avenira Limited has announced a strategic investment from Sichuan Hebang Biotechnology, with a two-tranche placement totaling A$4.5 million to fund various study works and provide general working capital. The deal allows Hebang significant influence, including the appointment of an Executive Chairman, two directors, a CEO, and a CFO to Avenira’s management team. If necessary approvals are not secured for the second tranche by the set deadline, Avenira is confident in its ability to secure alternative funding.
For further insights into AU:AEV stock, check out TipRanks’ Stock Analysis page.
